Grace An

Grace An is an experienced professional in biostatistics, currently serving as Director of Biostatistics at Revolution Medicines since November 2024. Previously, Grace held similar director roles at ALX Oncology and Ascendis Pharma, leading statistical efforts for pivotal cancer trials and regulatory submissions. Prior positions include Associate Director of Biostatistics at Seagen, where Grace contributed to the successful NDA submission for Tukysa, and Principal Biostatistician at Novartis, focusing on oncology trials. Grace began a career in research at the Cleveland Clinic and Johns Hopkins School of Medicine, after earning a Ph.D. in Biostatistics from UT MD Anderson Cancer Center UTHealth Houston, an M.S. from Case Western Reserve University, and a B.E. in Computer Science from Shanghai University.